



Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

Stephan Kloess^{1*}, Alessa Ede Valverde da Silva¹, Olaf Oberschmidt¹, Tanja Gardlowski¹, Nadine Matthies¹, Maulik Vyas², Lubomir Arseniev¹, Michael Heuser³, Elke Pogge von Strandmann⁴ and Ulrike Köhl¹

OPEN ACCESS

Approved by:

Frontiers in Immunology Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Stephan Kloess
kloess.stephan@mh-hannover.de

Specialty section:

This article was submitted to Alloimmunity and Transplantation, a section of the journal *Frontiers in Immunology*

Received: 17 September 2018

Accepted: 18 September 2018

Published: 08 October 2018

Citation:

Kloess S, Ede Valverde da Silva A, Oberschmidt O, Gardlowski T, Matthies N, Vyas M, Arseniev L, Heuser M, Pogge von Strandmann E and Köhl U (2018) Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset. *Front. Immunol.* 9:2326. doi: 10.3389/fimmu.2018.02326

¹ Institute for Cellular Therapeutics, IFB-Tx, Hannover Medical School (MHH), Hannover, Germany, ² Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany, ³ Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany, ⁴ Experimental Tumor Research, Center for Tumor Biology and Immunology, Philipps University Marburg, Marburg, Germany

Keywords: natural killer cells, natural killer group 2 member D, triplebodies, ULBP2, CD19, CD33, immunoligands, acute myeloid leukemia

A Corrigendum on

Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset by Kloess, S., Ede Valverde da Silva, A., Oberschmidt, O., Gardlowski, T., Matthies, N., Vyas, M., et al. *Front. Immunol.* (2017) 8:1100. doi: 10.3389/fimmu.2017.01100

In the original article, we neglected to include the following funding information:

This study was supported by a grant from the Deutsche Jose Carreras Leukämie-Stiftung to ES (DJCLS R 1408).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Kloess, Ede Valverde da Silva, Oberschmidt, Gardlowski, Matthies, Vyas, Arseniev, Heuser, Pogge von Strandmann and Köhl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.